Fluicell AB (publ)
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of mu… Read more
Market Cap & Net Worth: Fluicell AB (publ) (5J90)
Fluicell AB (publ) (F:5J90) has a market capitalization of $1.54 Million (€1.50 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #35475 globally and #4199 in its home market, demonstrating a 18.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fluicell AB (publ)'s stock price €1.09 by its total outstanding shares 1373703 (1.37 Million).
Fluicell AB (publ) Market Cap History: 2026 to 2026
Fluicell AB (publ)'s market capitalization history from 2026 to 2026. Data shows growth from $1.54 Million to $1.54 Million (0.00% CAGR).
Fluicell AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fluicell AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 5J90 by Market Capitalization
Companies near Fluicell AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to Fluicell AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Fluicell AB (publ) Historical Marketcap From 2026 to 2026
Between 2026 and today, Fluicell AB (publ)'s market cap moved from $1.54 Million to $ 1.54 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.54 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Fluicell AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.54 Million USD |
| MoneyControl | $1.54 Million USD |
| MarketWatch | $1.54 Million USD |
| marketcap.company | $1.54 Million USD |
| Reuters | $1.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.